We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...

Objective Patients with SLE have increased risk of both clinical cardiovascular disease (CVD) and subclinical atherosclerosis ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Objectives Lupus nephritis (LN) is a highly heterogenous disease with variable risks of end-stage kidney disease (ESKD) across histological classes and ethnic groups. Current remission criteria based ...

Objective Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential ...

Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare ...

Objectives To evaluate the diagnostic and prognostic performance of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in SLE and to integrate these biomarkers into an ...

Primary objective To evaluate histopathological renal response in re-biopsy after induction therapy and to correlate with the Target Renal Response (TRR) and secondary objective: to correlate serum ...

Objectives To explore the effects of anti-ribosomal P protein (anti-P) and anti-N-methyl-D-aspartic acid receptor subunit 2 (anti-NR2) autoantibodies on depression and cognitive dysfunction and their ...

Objectives Following the successful AURORA-1 and AURORA-2 trials, voclosporin was incorporated into the KDIGO 2024 clinical guidelines for the management of active Class III or IV lupus nephritis, ...

Objectives The 2023 EULAR recommendations for the management of SLE endorse stratifying disease activity into mild, moderate, and severe categories to guide treat-to-target (T2T) strategies. Both ...

Objective Lupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin ...